# Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer

> **NCT00733850** · PHASE2 · COMPLETED · sponsor: **KangLaiTe USA** · enrollment: 85 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Kanglaite Injection plus gemcitabine
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00733850
- **Lead sponsor:** KangLaiTe USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2015-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00733850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00733850, "Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00733850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*